Can a daily pill stop leukemia relapse after transplant?

NCT ID NCT07250087

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests the safety and best dose of asciminib, a daily pill, in adults with a certain type of leukemia (Ph+ ALL) who have already received a stem cell transplant or CAR T therapy. The goal is to see if taking asciminib afterward can help prevent the cancer from returning. About 36 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) leukemia, acute lymphocytic, susceptibility to, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.